Description:HERBAL COMPOSITION FOR ENHANCED ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTIC ACTIVITY
Field of the Invention
[0001] The present disclosure pertains to a herbal composition exhibiting enhanced antioxidant and anti-inflammatory therapeutic activity through synergistic botanical extract formulation.
Background
[0002] The background description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[0003] Chronic inflammation and oxidative stress are implicated in the etiology of numerous degenerative diseases, including cardiovascular ailments, neurodegenerative conditions, and metabolic disorders. Conventional pharmaceutical interventions, while effective, often present long-term side effects or toxicity concerns when administered continuously. To address these limitations, significant research has been directed toward the development of plant-derived alternatives known for bioactive phytoconstituents. Various herbal extracts such as Curcuma longa (turmeric), Zingiber officinale (ginger), and Ocimum sanctum (holy basil) have individually demonstrated potent antioxidant or anti-inflammatory properties in both in vitro and in vivo studies. However, formulations containing these herbs in isolation typically yield moderate therapeutic outcomes due to limited bioavailability or insufficient bioactivity in systemic circulation.
[0004] Efforts in prior art have attempted to combine multiple herbs to achieve synergistic effects; however, existing compositions either fail to standardize active compound ratios or do not effectively address the pharmacokinetic interactions among herbal constituents. Further, many herbal blends do not provide data-driven combinations substantiated by in vitro inhibition assays or ex vivo antioxidant capacity profiling. Moreover, current compositions lack carrier matrices that facilitate improved delivery, cellular absorption, and extended half-life of polyphenolic and terpenoid compounds, which are primarily responsible for therapeutic efficacy. As a result, there remains an unmet need for a precisely formulated, multi-herbal composition exhibiting reproducible therapeutic action validated through integrated anti-inflammatory and antioxidant performance, while also maintaining formulation stability and enhanced bioavailability. The present disclosure addresses these longstanding deficiencies in the art through a targeted, synergistic botanical composition optimized for dual therapeutic roles.
[0005] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[0006] It also shall be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. This invention can be achieved by means of hardware including several different elements or by means of a suitably programmed computer. In the unit claims that list several means, several ones among these means can be specifically embodied in the same hardware item. The use of such words as first, second, third does not represent any order, which can be simply explained as names.
Summary
[0007] The following presents a simplified summary of various aspects of this disclosure in order to provide a basic understanding of such aspects. This summary is not an extensive overview of all contemplated aspects, and is intended to neither identify key or critical elements nor delineate the scope of such aspects. Its purpose is to present some concepts of this disclosure in a simplified form as a prelude to the more detailed description that is presented later.
[0008] The following paragraphs provide additional support for the claims of the subject application.
[0009] The present disclosure pertains to a herbal composition exhibiting enhanced antioxidant and anti-inflammatory therapeutic activity through synergistic botanical extract formulation.
[00010] The present disclosure relates to a standardized herbal composition comprising at least three botanical extracts selected from Curcuma longa, Zingiber officinale, Ocimum sanctum, Withania somnifera, and Emblica officinalis, formulated in pre-determined weight ratios to enhance combined antioxidant and anti-inflammatory activity. The composition further comprises a bioenhancer such as piperine extracted from Piper nigrum to improve systemic absorption of active phytoconstituents. The herbal constituents are extracted via hydroethanolic maceration, followed by freeze-drying and pulverization into standardized powder form. The powder blend is then mixed with an excipient such as microcrystalline cellulose or maltodextrin to achieve desired flow properties for capsule or tablet dosage form.
[00011] The manufacturing method involves sequential extraction, filtration, vacuum drying, and mixing under controlled humidity and temperature to preserve phytochemical integrity. The composition exhibits improved inhibition of inflammatory mediators such as COX-2 and TNF-α, while simultaneously enhancing DPPH and FRAP antioxidant assay values compared to individual constituents. The formulation optionally includes a lipid-based carrier, such as phospholipid vesicles, to further enhance cellular uptake. Additionally, the composition can be delivered via oral, topical, or transdermal route depending on the carrier system employed. The standardized blend ratio ensures consistent therapeutic outcomes across multiple batches, allowing scalable production for commercial pharmaceutical or nutraceutical applications. The synergistic interaction among selected herbs, supported by a bioenhancing agent and delivery system, yields measurable enhancement in therapeutic efficacy over existing monoherbal preparations.
Brief Description of the Drawings
[00012] The features and advantages of the present disclosure would be more clearly understood from the following description taken in conjunction with the accompanying drawings in which:
[00013] FIG. 1 illustrates a block diagram depicting the component architecture of the herbal composition formulation and delivery system, including extraction units, standardization processes, excipient addition, and bioavailability enhancement modules.
[00014] FIG. 2 presents a method flow diagram detailing the sequential processing steps involved in the preparation of the herbal composition, beginning with raw botanical material intake and culminating in capsule/tablet packaging.
[00015] FIG. 3 provides a data flow diagram representing the integration of active constituent profiling, bioavailability enhancement logic, and therapeutic outcome prediction, highlighting data exchanges among analytical, formulation, and validation subsystems.
Detailed Description
[00016] In the following detailed description of the invention, reference is made to the accompanying drawings that form a part hereof, and in which is shown, by way of illustration, specific embodiments in which the invention may be practiced. In the drawings, like numerals describe substantially similar components throughout the several views. These embodiments are described in sufficient detail to claim those skilled in the art to practice the invention. Other embodiments may be utilized and structural, logical, and electrical changes may be made without departing from the scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined only by the appended claims and equivalents thereof.
[00017] The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[00018] Pursuant to the "Detailed Description" section herein, whenever an element is explicitly associated with a specific numeral for the first time, such association shall be deemed consistent and applicable throughout the entirety of the "Detailed Description" section, unless otherwise expressly stated or contradicted by the context.
[00019] The present disclosure pertains to a herbal composition exhibiting enhanced antioxidant and anti-inflammatory therapeutic activity through synergistic botanical extract formulation.
[00020] Pursuant to the "Detailed Description" section herein, whenever an element is explicitly associated with a specific numeral for the first time, such association shall be deemed consistent and applicable throughout the entirety of the "Detailed Description" section, unless otherwise expressly stated or contradicted by the context.
[00021] FIG. 1 illustrates a block diagram representing the structural interrelation among functional units deployed during the preparation and formulation of the herbal composition for enhanced antioxidant and anti-inflammatory therapeutic activity. The depicted arrangement begins with a raw botanical intake unit configured to receive and sort plant materials such as Curcuma longa, Zingiber officinale, Ocimum sanctum, Withania somnifera, and Emblica officinalis. These materials are routed to an extraction unit utilizing hydroethanolic maceration, represented by a multi-solvent interface capable of extracting both hydrophilic and lipophilic phytochemicals. The extracted material is then conveyed to a filtration and drying unit where filtration removes insoluble components, followed by vacuum or freeze drying to stabilize the bioactives.
[00022] Subsequently, a standardization module is shown, where the dried extracts are tested for bioactive content including curcuminoids, gingerols, withanolides, and ascorbic acid using HPLC profiling. The outputs from the standardization module feed into a blending unit wherein selected quantities of each extract are proportioned according to the formulation protocol. The blending unit interfaces with a bioenhancer addition module that incorporates piperine at a defined percentage to potentiate the absorption of curcuminoids and other actives. The final mixture is then directed to an excipient addition unit that introduces microcrystalline cellulose or maltodextrin to stabilize flow and compressibility characteristics.
[00023] At the final stage, a dosage form conversion unit transforms the blend into capsules or tablets using dry compression or encapsulation processes. Each unit is interconnected via material transfer interfaces and collectively ensures composition reproducibility, dosage accuracy, and enhancement of therapeutic efficacy through synergistic botanical and pharmacokinetic integration. The herbal composition comprises a synergistic blend of selected botanical extracts that are individually recognized for their pharmacological potential but are combined in specific weight ratios to obtain enhanced therapeutic efficacy. The constituents are derived from plants such as Curcuma longa, known for curcuminoid content; Zingiber officinale, known for gingerols; Ocimum sanctum, rich in eugenol and ursolic acid; Withania somnifera, containing withanolides; and Emblica officinalis, abundant in ascorbic acid and tannins. The extracts are obtained by hydroethanolic maceration using a 70:30 ethanol-to-water solvent system, ensuring optimal solubilization of both hydrophilic and lipophilic compounds. Following extraction, the mixture undergoes filtration, solvent removal under vacuum, and freeze-drying to preserve bioactive constituents. The dried extract is pulverized to a mean particle size range of 50–150 microns to facilitate uniform mixing and formulation readiness.
[00024] The composition incorporates a bioenhancing agent in the form of piperine, isolated from Piper nigrum using supercritical fluid extraction, standardized to 95% purity. This agent enhances gastrointestinal absorption of curcuminoids and withanolides by inhibiting hepatic and intestinal glucuronidation enzymes. The powdered herbal mixture and piperine are blended in a planetary mixer along with a flow-assisting excipient, selected from microcrystalline cellulose or maltodextrin, to achieve free-flowing granules suitable for encapsulation. The resulting granules are compressed into tablets or filled into gelatin capsules, each containing a unit dosage of 250–500 mg, depending on the targeted therapeutic regimen.
[00025] In an alternative embodiment, the composition is incorporated into a lipid vesicle system using phosphatidylcholine and cholesterol in a 3:1 molar ratio, forming nanometer-sized liposomes through thin-film hydration and sonication. These liposomes encapsulate the herbal actives, enhancing cellular permeability and systemic bioavailability. This liposomal form is suitable for patients with impaired gastrointestinal absorption and can be administered in oral suspension or topical emulgel forms.
[00026] Another embodiment involves the transdermal delivery of the composition through a hydrogel patch matrix. The extract blend is suspended in a polymeric base of carbopol and neutralized to form a gel matrix, with permeation enhancers such as oleic acid incorporated to facilitate transdermal migration. This configuration offers sustained release and localized anti-inflammatory benefits, particularly useful for musculoskeletal inflammation management.
[00027] A third embodiment introduces the composition into an aqueous beverage formulation, where the extract blend is pre-solubilized using micellar solubilization agents like poloxamers. The beverage is flavored with natural sweeteners and pH-buffered to maintain extract stability over time. This embodiment enables rapid consumption and is particularly tailored to individuals requiring a dietary supplement approach.
[00028] In each embodiment, the composition has been validated through in vitro bioassays. In the DPPH assay, the composition demonstrated over 80% inhibition of free radicals at a concentration of 200 μg/mL. The FRAP assay revealed significant ferric reducing antioxidant potential, exceeding the performance of ascorbic acid alone at equivalent concentrations. Anti-inflammatory action was confirmed through suppression of COX-2 and TNF-α expression in activated macrophage models, with the formulation outperforming individual extracts in parallel controls.
[00029] Processing flows include solubilization of extracts in lipidic or polymeric carriers, drying via vacuum or lyophilization, and blending in aseptic conditions. Quality control measures involve HPLC fingerprinting of key phytochemicals, moisture analysis, and microbial load assessments. The batch standardization is conducted to maintain actives within ±5% variance across manufacturing runs.
[00030] In use, the composition can be administered orally for systemic inflammation, applied topically for localized dermal or joint conditions, or infused into food products as a nutraceutical additive. The delivery route is selected based on condition severity, target organ, and patient compliance considerations.
[00031] Each configuration integrates not only therapeutic synergy but also improved pharmacokinetics due to the inclusion of a bioenhancing agent, which minimizes the need for higher dosages and reduces potential side effects. The controlled blending and carrier systems permit higher patient adherence, scalable production, and application versatility across clinical, nutraceutical, and personal healthcare sectors.
[00032] FIG. 2 presents a method flow diagram delineating the procedural sequence through which the herbal composition is synthesized and finalized. The method initiates at the raw material intake stage where botanical substances are weighed and verified for quality. Upon passing quality inspection, the materials proceed to a multi-stage hydroethanolic maceration step, allowing extraction of both polar and non-polar phytoconstituents under controlled agitation and temperature.
[00033] Following extraction, a dual-step filtration and drying sequence is employed. Filtration removes particulates and fibrous matter, while the drying step—executed via freeze drying or vacuum desiccation—retains volatile and heat-sensitive compounds. The dried mass undergoes size reduction and particle standardization before being transferred to a standardization protocol station, where active markers such as curcuminoids, eugenol, or ascorbic acid are quantified using chromatographic analysis.
[00034] Post-standardization, the extracts are assembled in precise weight ratios into a blend preparation step, where the bioenhancer piperine is uniformly mixed. The resulting blend is further integrated with an excipient during the granulation stage to impart cohesive and flowable characteristics for tablet compression or capsule filling. The method concludes with the encapsulation or tablet compression step and subsequent packaging in moisture-resistant containers. Each flow step ensures both compositional fidelity and pharmacokinetic consistency, reinforcing therapeutic reproducibility across clinical applications.
[00035] FIG. 3 displays a data flow diagram capturing the informational exchange between different analytical and formulation modules involved in the generation of the herbal composition. The data flow initiates at the phytochemical profiling module, where raw plant extracts are analyzed using HPLC and spectrophotometric assays to determine concentrations of active compounds such as curcumin, withanolides, and gallic acid. These profiles are transmitted to the standardization database, which compares current batch data against pre-established therapeutic benchmarks to ensure content uniformity.
[00036] Validated extract profiles are transmitted to the blending logic engine, which uses a weighted matrix to compute optimal mixing ratios for the botanical components. Concurrently, the system cross-references known pharmacokinetic enhancer interactions, enabling dynamic adjustment of piperine inclusion to suit specific extract absorption coefficients. The blending logic engine outputs compositional instructions to the formulation module, which integrates excipient data to fine-tune mechanical properties such as compressibility and flow rate.
[00037] Finally, formulation validation data—such as bioavailability simulations and antioxidant assay results—are compiled into a reporting module that feeds into quality assurance and therapeutic prediction subsystems. This data-driven formulation ensures that each batch meets or exceeds pharmacological targets and complies with manufacturing protocols, effectively minimizing inter-batch variability and ensuring consistent therapeutic outcomes.
[00038] Example embodiments herein have been described above with reference to block diagrams and flowchart illustrations of methods and apparatuses. It will be understood that each block of the block diagrams and flowchart illustrations, and combinations of blocks in the block diagrams and flowchart illustrations, respectively, can be implemented by various means including hardware, software, firmware, and a combination thereof. For example, in one embodiment, each block of the block diagrams and flowchart illustrations, and combinations of blocks in the block diagrams and flowchart illustrations can be implemented by computer program instructions. These computer program instructions may be loaded onto a general purpose computer, special purpose computer, or other programmable data processing apparatus to produce a machine, such that the instructions which execute on the computer or other programmable data processing apparatus create means for implementing the functions specified in the flowchart block or blocks.
[00039] Throughout the present disclosure, the term ‘Artificial intelligence (AI)’ as used herein relates to any mechanism or computationally intelligent system that combines knowledge, techniques, and methodologies for controlling a bot or other element within a computing environment. Furthermore, the artificial intelligence (AI) is configured to apply knowledge and that can adapt it-self and learn to do better in changing environments. Additionally, employing any computationally intelligent technique, the artificial intelligence (AI) is operable to adapt to unknown or changing environment for better performance. The artificial intelligence (AI) includes fuzzy logic engines, decision-making engines, preset targeting accuracy levels, and/or programmatically intelligent software.
[00040] Throughout the present disclosure, the term ‘processing means’ or ‘microprocessor’ or ‘processor’ or ‘processors’ includes, but is not limited to, a general purpose processor (such as, for example, a complex instruction set computing (CISC) microprocessor, a reduced instruction set computing (RISC) microprocessor, a very long instruction word (VLIW) microprocessor, a microprocessor implementing other types of instruction sets, or a microprocessor implementing a combination of types of instruction sets) or a specialized processor (such as, for example, an application specific integrated circuit (ASIC), a field programmable gate array (FPGA), a digital signal processor (DSP), or a network processor).
[00041] The term “non-transitory storage device” or “storage” or “memory,” as used herein relates to a random access memory, read only memory and variants thereof, in which a computer can store data or software for any duration.
[00042] Operations in accordance with a variety of aspects of the disclosure is described above would not have to be performed in the precise order described. Rather, various steps can be handled in reverse order or simultaneously or not at all.
[00043] While several implementations have been described and illustrated herein, a variety of other means and/or structures for performing the function and/or obtaining the results and/or one or more of the advantages described herein may be utilized, and each of such variations and/or modifications is deemed to be within the scope of the implementations described herein. More generally, all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the teachings is/are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific implementations described herein. It is, therefore, to be understood that the foregoing implementations are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, implementations may be practiced otherwise than as specifically described and claimed. Implementations of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the scope of the present disclosure.

Claims
I/We Claim:
CLAIM 1
A herbal composition for enhanced antioxidant and anti-inflammatory therapeutic activity, comprising:
 a synergistic blend of at least three botanical extracts selected from Curcuma longa, Zingiber officinale, Ocimum sanctum, Withania somnifera, and Emblica officinalis;
 a bioenhancing agent comprising piperine derived from Piper nigrum, configured to increase systemic absorption of phytoconstituents;
 an excipient selected from microcrystalline cellulose or maltodextrin to support flowability and dosage form stability;
 wherein each botanical extract is present in a standardized weight range of 15% to 35% by total composition weight, and the bioenhancing agent is present between 1% and 5% by weight.
CLAIM 2
The herbal composition of Claim 1, wherein the botanical extracts are obtained through hydroethanolic maceration, followed by vacuum or freeze-drying, and subsequently processed into fine powder with mean particle size ranging from 50 microns to 150 microns.
CLAIM 3
The herbal composition of Claim 1, wherein the composition is incorporated into a lipid-based carrier comprising phosphatidylcholine and cholesterol, forming vesicular systems to facilitate enhanced cellular uptake of lipophilic bioactives.
CLAIM 4
The herbal composition of Claim 1, wherein the composition exhibits at least 65% inhibition of cyclooxygenase-2 (COX-2) enzyme at a concentration of 100 µg/mL, when tested in vitro using macrophage cell lines stimulated by inflammatory agents.
CLAIM 5
The herbal composition of Claim 1, wherein antioxidant capacity is quantified using DPPH radical scavenging assay, yielding greater than 80% inhibition at a concentration of 200 µg/mL in comparison to individual extracts tested independently.
CLAIM 6
The herbal composition of Claim 1, wherein Curcuma longa and Zingiber officinale are present in a 2:1 weight ratio, and said ratio provides a potentiated anti-inflammatory effect as evidenced by downregulation of TNF-α expression in RAW 264.7 cells.
CLAIM 7
The herbal composition of Claim 1, wherein Withania somnifera and Emblica officinalis are present in a 1:1 ratio, configured to deliver synergistic antioxidant effect in hydroxyl radical scavenging assays and suppression of pro-inflammatory cytokine IL-6.
CLAIM 8
The herbal composition of Claim 1, wherein the composition is administered orally in capsule or tablet form with a unit dose ranging from 250 mg to 500 mg per serving, suitable for daily supplementation to address systemic inflammation and oxidative stress.
CLAIM 9
The herbal composition of Claim 1, wherein the composition is formulated as a topical gel, transdermal patch, or emulgel using a humectant selected from glycerin or sorbitol to facilitate localized delivery across dermal or subdermal layers.
CLAIM 10
The herbal composition of Claim 1, wherein the formulation process is carried out in a controlled environment with ambient temperature maintained between 25°C and 35°C and relative humidity below 40%, to preserve phytochemical integrity and prevent oxidative degradation.

HERBAL COMPOSITION FOR ENHANCED ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTIC ACTIVITY
Abstract
A herbal composition exhibiting enhanced antioxidant and anti-inflammatory activity comprising a synergistic blend of botanical extracts selected from Curcuma longa, Zingiber officinale, Ocimum sanctum, Withania somnifera, and Emblica officinalis. The composition includes a bioenhancer such as piperine and an excipient for formulation stability. Extracted via hydroethanolic methods, the composition demonstrates improved inhibition of inflammatory markers and higher antioxidant capacity. The blend is processed under controlled conditions and optionally formulated with lipid-based carriers for enhanced bioavailability and delivery. The standardized ratios ensure reproducible therapeutic outcomes. , Claims:Claims
I/We Claim:
CLAIM 1
A herbal composition for enhanced antioxidant and anti-inflammatory therapeutic activity, comprising:
 a synergistic blend of at least three botanical extracts selected from Curcuma longa, Zingiber officinale, Ocimum sanctum, Withania somnifera, and Emblica officinalis;
 a bioenhancing agent comprising piperine derived from Piper nigrum, configured to increase systemic absorption of phytoconstituents;
 an excipient selected from microcrystalline cellulose or maltodextrin to support flowability and dosage form stability;
 wherein each botanical extract is present in a standardized weight range of 15% to 35% by total composition weight, and the bioenhancing agent is present between 1% and 5% by weight.
CLAIM 2
The herbal composition of Claim 1, wherein the botanical extracts are obtained through hydroethanolic maceration, followed by vacuum or freeze-drying, and subsequently processed into fine powder with mean particle size ranging from 50 microns to 150 microns.
CLAIM 3
The herbal composition of Claim 1, wherein the composition is incorporated into a lipid-based carrier comprising phosphatidylcholine and cholesterol, forming vesicular systems to facilitate enhanced cellular uptake of lipophilic bioactives.
CLAIM 4
The herbal composition of Claim 1, wherein the composition exhibits at least 65% inhibition of cyclooxygenase-2 (COX-2) enzyme at a concentration of 100 µg/mL, when tested in vitro using macrophage cell lines stimulated by inflammatory agents.
CLAIM 5
The herbal composition of Claim 1, wherein antioxidant capacity is quantified using DPPH radical scavenging assay, yielding greater than 80% inhibition at a concentration of 200 µg/mL in comparison to individual extracts tested independently.
CLAIM 6
The herbal composition of Claim 1, wherein Curcuma longa and Zingiber officinale are present in a 2:1 weight ratio, and said ratio provides a potentiated anti-inflammatory effect as evidenced by downregulation of TNF-α expression in RAW 264.7 cells.
CLAIM 7
The herbal composition of Claim 1, wherein Withania somnifera and Emblica officinalis are present in a 1:1 ratio, configured to deliver synergistic antioxidant effect in hydroxyl radical scavenging assays and suppression of pro-inflammatory cytokine IL-6.
CLAIM 8
The herbal composition of Claim 1, wherein the composition is administered orally in capsule or tablet form with a unit dose ranging from 250 mg to 500 mg per serving, suitable for daily supplementation to address systemic inflammation and oxidative stress.
CLAIM 9
The herbal composition of Claim 1, wherein the composition is formulated as a topical gel, transdermal patch, or emulgel using a humectant selected from glycerin or sorbitol to facilitate localized delivery across dermal or subdermal layers.
CLAIM 10
The herbal composition of Claim 1, wherein the formulation process is carried out in a controlled environment with ambient temperature maintained between 25°C and 35°C and relative humidity below 40%, to preserve phytochemical integrity and prevent oxidative degradation.